Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Growing Teratoma Syndrome of the Liver in a 22-Year-Old Female.

O'Reilly D, Alken S, Fiore B, Dooley L, Prior L, Hoti E, Fennelly D.

J Adolesc Young Adult Oncol. 2020 Feb;9(1):124-127. doi: 10.1089/jayao.2019.0081. Epub 2019 Sep 23.

PMID:
31545120
2.

KH-Type Splicing Regulatory Protein Controls Colorectal Cancer Cell Growth and Modulates the Tumor Microenvironment.

Caiazza F, Oficjalska K, Tosetto M, Phelan JJ, Noonan S, Martin P, Killick K, Breen L, O'Neill F, Nolan B, Furney S, Power R, Fennelly D, Craik CS, O'Sullivan J, Sheahan K, Doherty GA, Ryan EJ.

Am J Pathol. 2019 Oct;189(10):1916-1932. doi: 10.1016/j.ajpath.2019.07.004. Epub 2019 Aug 9.

3.

Effects of CDX2 on prognosis and chemotherapy responsiveness in mismatch repair-deficient colorectal cancer.

Ryan ÉJ, Creavin B, Khaw YL, Kelly ME, Mohan HM, Geraghty R, Ryan EJ, Kennelly R, Hanly A, Martin ST, Fennelly D, McDermott R, Gibbons D, O'Connell PR, Sheahan K, Winter DC.

BJS Open. 2018 Jul 24;2(6):456-463. doi: 10.1002/bjs5.91. eCollection 2018 Dec.

4.

Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.

Gullo G, Walsh N, Fennelly D, Bose R, Walshe J, Tryfonopoulos D, O'Mahony K, Hammond L, Silva N, McDonnell D, Ballot J, Quinn C, McDermott EW, Evoy D, Prichard R, Geraghty J, Amstrong J, Crown J.

Br J Cancer. 2018 Aug;119(3):374-380. doi: 10.1038/s41416-018-0114-x. Epub 2018 May 18.

5.

Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment.

Noonan SA, Morrissey ME, Martin P, Biniecka M, Ó'Meachair S, Maguire A, Tosetto M, Nolan B, Hyland J, Sheahan K, O'Donoghue D, Mulcahy H, Fennelly D, O'Sullivan J.

Oncotarget. 2018 Jan 19;9(12):10536-10548. doi: 10.18632/oncotarget.24276. eCollection 2018 Feb 13.

6.

Multivisceral Resection for Locally Invasive Colorectal Liver Metastases: Outcomes of a Matched Cohort Analysis.

Hand F, Sanabria Mateos R, Durand M, Fennelly D, McDermott R, Maguire D, Geoghegan J, Winter D, Hoti E.

Dig Surg. 2018;35(6):514-519. doi: 10.1159/000485198. Epub 2018 Jan 18.

PMID:
29346790
7.

Microsatellite instability is associated with reduced disease specific survival in stage III colon cancer.

Mohan HM, Ryan E, Balasubramanian I, Kennelly R, Geraghty R, Sclafani F, Fennelly D, McDermott R, Ryan EJ, O'Donoghue D, Hyland JM, Martin ST, O'Connell PR, Gibbons D, Winter D, Sheahan K.

Eur J Surg Oncol. 2016 Nov;42(11):1680-1686. doi: 10.1016/j.ejso.2016.05.013. Epub 2016 Jun 22.

PMID:
27370895
8.

Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.

Murphy AG, Casey R, Maguire A, Tosetto M, Butler CT, Conroy E, Reynolds AL, Sheahan K, O'Donoghue D, Gallagher WM, Fennelly D, Kennedy BN, O'Sullivan J.

Sci Rep. 2016 Oct 14;6:34523. doi: 10.1038/srep34523.

9.

Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up.

Murtagh G, Lyons T, O'Connell E, Ballot J, Geraghty L, Fennelly D, Gullo G, Ledwidge M, Crown J, Gallagher J, Watson C, McDonald KM, Walshe JM.

Breast Cancer Res Treat. 2016 Apr;156(3):501-506. doi: 10.1007/s10549-016-3781-4. Epub 2016 Apr 9.

PMID:
27060913
10.

Visceral Adiposity is a Risk Factor for Poor Prognosis in Colorectal Cancer Patients Receiving Adjuvant Chemotherapy.

Lee CS, Murphy DJ, McMahon C, Nolan B, Cullen G, Mulcahy H, Sheahan K, Barnes E, Fennelly D, Ryan EJ, Doherty GA.

J Gastrointest Cancer. 2015 Sep;46(3):243-50. doi: 10.1007/s12029-015-9709-0.

PMID:
25832480
11.

Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.

Caiazza F, Elliott L, Fennelly D, Sheahan K, Doherty GA, Ryan EJ.

Biomark Med. 2015;9(4):363-75. doi: 10.2217/bmm.15.5. Review.

PMID:
25808440
12.

Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer.

Martin P, Noonan S, Mullen MP, Scaife C, Tosetto M, Nolan B, Wynne K, Hyland J, Sheahan K, Elia G, O'Donoghue D, Fennelly D, O'Sullivan J.

BMC Cancer. 2014 Nov 27;14:887. doi: 10.1186/1471-2407-14-887.

13.

Gamma band activity and the P3 reflect post-perceptual processes, not visual awareness.

Pitts MA, Padwal J, Fennelly D, Martínez A, Hillyard SA.

Neuroimage. 2014 Nov 1;101:337-50. doi: 10.1016/j.neuroimage.2014.07.024. Epub 2014 Jul 22.

14.

Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive.

O'Toole A, Michielsen AJ, Nolan B, Tosetto M, Sheahan K, Mulcahy HE, Winter DC, Hyland JM, O'Connell PR, Fennelly D, O'Donoghue D, O'Sullivan J, Doherty GA, Ryan EJ.

Br J Cancer. 2014 Aug 26;111(5):927-32. doi: 10.1038/bjc.2014.367. Epub 2014 Jul 24.

15.

Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience.

Duignan S, Maguire D, Ravichand CS, Geoghegan J, Hoti E, Fennelly D, Armstrong J, Rock K, Mohan H, Traynor O.

HPB (Oxford). 2014 Jan;16(1):91-8. doi: 10.1111/hpb.12082. Epub 2013 Apr 18.

16.

Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.

Tamagno G, Sheahan K, Skehan SJ, Geoghegan JG, Fennelly D, Collins CD, Maguire D, Traynor O, Brophy DP, Cantwell C, Swan N, McGowan L, O'Toole D, O'Shea D.

Endocrine. 2013 Oct;44(2):504-9. doi: 10.1007/s12020-013-9910-5. Epub 2013 Mar 8.

PMID:
23471696
17.

Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy.

Ward F, Dunne O, Crotty TB, Fennelly D, Watson A, Holian J.

Ir Med J. 2012 May;105(5):148-9.

PMID:
22803494
18.

Inhibition of dendritic cell maturation by the tumor microenvironment correlates with the survival of colorectal cancer patients following bevacizumab treatment.

Michielsen AJ, Noonan S, Martin P, Tosetto M, Marry J, Biniecka M, Maguire AA, Hyland JM, Sheahan KD, O'Donoghue DP, Mulcahy HE, Fennelly D, Ryan EJ, O'Sullivan JN.

Mol Cancer Ther. 2012 Aug;11(8):1829-37. doi: 10.1158/1535-7163.MCT-12-0162. Epub 2012 Jun 6.

19.

Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.

McHugh JC, Tryfonopoulos D, Fennelly D, Crown J, Connolly S.

Eur J Cancer Care (Engl). 2012 Nov;21(6):782-9. doi: 10.1111/j.1365-2354.2012.01361.x. Epub 2012 May 17.

PMID:
22594346
20.

Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review.

Shireen R, Brennan D, Flannelly G, Fennelly D, Lenehan P, Foley M.

Ir Med J. 2012 Feb;105(2):47-50.

PMID:
22455239
21.

A prospective analysis of patient outcome following treatment of T3 rectal cancer with neo-adjuvant chemoradiotherapy and transanal excision.

Kennelly RP, Heeney A, White A, Fennelly D, Sheahan K, Hyland JM, O'Connell PR, Winter DC.

Int J Colorectal Dis. 2012 Jun;27(6):759-64. doi: 10.1007/s00384-011-1388-0. Epub 2011 Dec 17.

PMID:
22173716
22.

Primary cardiac lymphoma: diagnostic tools and treatment challenges.

Bambury R, Gallagher F, Dodd JD, Fennelly D.

Ir J Med Sci. 2011 Mar;180(1):271-3. doi: 10.1007/s11845-009-0446-x. Epub 2009 Nov 17.

PMID:
19921311
23.

Hepatocellular carcinoma complicating cystic fibrosis related liver disease.

O'Donnell DH, Ryan R, Hayes B, Fennelly D, Gibney RG.

J Cyst Fibros. 2009 Jul;8(4):288-90. doi: 10.1016/j.jcf.2009.05.002. Epub 2009 May 26.

24.

Nuclear oxidative damage correlates with poor survival in colorectal cancer.

Sheridan J, Wang LM, Tosetto M, Sheahan K, Hyland J, Fennelly D, O'Donoghue D, Mulcahy H, O'Sullivan J.

Br J Cancer. 2009 Jan 27;100(2):381-8. doi: 10.1038/sj.bjc.6604821. Epub 2008 Dec 9.

25.

Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer.

Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, O'Donoghue D, Sheahan K.

Am J Surg Pathol. 2009 Jan;33(1):134-41. doi: 10.1097/PAS.0b013e318184cd55.

PMID:
18971777
26.

A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.

Beddy D, Hyland JM, Winter DC, Lim C, White A, Moriarty M, Armstrong J, Fennelly D, Gibbons D, Sheahan K.

Ann Surg Oncol. 2008 Dec;15(12):3471-7. doi: 10.1245/s10434-008-0149-y. Epub 2008 Oct 10.

PMID:
18846402
27.

Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy.

Collins D, Ridgway PF, Winter DC, Fennelly D, Evoy D.

Eur J Surg Oncol. 2009 Apr;35(4):444-6. doi: 10.1016/j.ejso.2008.02.013. Epub 2008 Apr 15. No abstract available.

PMID:
18417314
28.

Multiple metastases to skeletal muscle from carcinoma of the esophagus detected by FDG PET-CT imaging.

Heffernan E, Fennelly D, Collins CD.

Clin Nucl Med. 2006 Dec;31(12):810-1.

PMID:
17117081
29.

Common critical pathways in embryogenesis and cancer.

Kelleher FC, Fennelly D, Rafferty M.

Acta Oncol. 2006;45(4):375-88. Review.

PMID:
16760173
30.

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.

O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J.

Cancer Chemother Pharmacol. 2007 Jan;59(1):79-87. Epub 2006 Apr 27.

PMID:
16642371
31.

Mutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer.

Fox EJ, Leahy DT, Geraghty R, Mulcahy HE, Fennelly D, Hyland JM, O'Donoghue DP, Sheahan K.

J Mol Diagn. 2006 Feb;8(1):68-75.

32.

Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D, Sheahan K.

Histopathology. 2005 Aug;47(2):141-6.

PMID:
16045774
33.

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.

Schoemaker NE, Kuppens IE, Moiseyenko V, Glimelius B, Kjaer M, Starkhammer H, Richel DJ, Smaaland R, Bertelsen K, Poulsen JP, Voznyi E, Norum J, Fennelly D, Tveit KM, Garin A, Gruia G, Mourier A, Sibaud D, Lefebvre P, Beijnen JH, Schellens JH, ten Bokkel Huinink WW.

Br J Cancer. 2004 Oct 18;91(8):1434-41.

34.
35.

Peritoneal involvement in stage II colon cancer.

Lennon AM, Mulcahy HE, Hyland JM, Lowry C, White A, Fennelly D, Murphy JJ, O'Donoghue DP, Sheahan K.

Am J Clin Pathol. 2003 Jan;119(1):108-13.

PMID:
12520705
36.

Extraskeletal Ewing's sarcoma: a case report and review of the literature.

Kennedy JG, Eustace S, Caulfield R, Fennelly DJ, Hurson B, O'Rourke KS.

Spine (Phila Pa 1976). 2000 Aug 1;25(15):1996-9. Review.

PMID:
10908947
37.

Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.

Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L.

J Clin Oncol. 1999 Jan;17(1):93-100.

PMID:
10458222
38.

Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.

Rigas JR, Kris MG, Miller VA, Pisters KM, Heelan RT, Grant SC, Fennelly DW, Chou TC, Sirotnak FM.

Ann Oncol. 1999 May;10(5):601-3.

39.

Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.

Husain A, Sabbatini P, Spriggs D, Fennelly D, Aghajanian C, Barakat R, Curtin J, Venkatraman E, Hoskins W, Markman M.

Gynecol Oncol. 1999 Apr;73(1):96-101.

PMID:
10094887
40.

Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.

D'Andrea G, Fennelly D, Norton L, Baselga J, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD.

Clin Cancer Res. 1999 Feb;5(2):275-9.

41.

New chemotherapy combinations with docetaxel in the treatment of patients with non-small cell lung cancer.

Donnellan P, Armstrong J, Rowan S, Fennelly D, Lynch V, McDonnell T, McNicholas W, Crown J.

Semin Oncol. 1998 Jun;25(3 Suppl 8):20-3.

PMID:
9704672
42.

Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.

Aghajanian C, Fennelly D, Shapiro F, Waltzman R, Almadrones L, O'Flaherty C, O'Conner K, Venkatraman E, Barakat R, Curtin J, Brown C, Reich L, Wuest D, Norton L, Hoskins W, Spriggs DR.

J Clin Oncol. 1998 May;16(5):1852-60.

PMID:
9586901
43.

Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.

Hudis C, Riccio L, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Lebwohl D, Moynahan M, Raptis G, Surbone A, Sklarin N, Yao TJ, Keefe D, Norton L.

Cancer Invest. 1998;16(2):67-71. No abstract available.

PMID:
9512671
44.

Phase II study of semisynthetic paclitaxel in metastatic breast cancer.

Hudis C, Riccio L, Holmes F, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Moynahan M, Raptis G, Sklarin N, Surbone A, Uhlenhopp M, Maickel N, Yao TJ, Hellmann S, Usakewicz J, Hortobagyi G, Norton L.

Eur J Cancer. 1997 Nov;33(13):2198-202.

PMID:
9470806
45.

Salvage weekly paclitaxel in recurrent ovarian cancer.

Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-62-S15-67.

PMID:
9346225
46.

Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience.

Seidman AD, Hudis CA, Raptis G, Baselga J, Fennelly D, Norton L.

Oncology (Williston Park). 1997 Mar;11(3 Suppl 2):20-8. Review.

47.

Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer.

Fennelly DW, Aghajanian C, Shapiro F, O'Flaherty C, O'Connor K, Curtin JP, Crown JP, Hoskins WJ, Spriggs DR.

Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-26-S2-30.

PMID:
9045332
48.

Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease.

Barakat RR, Fennelly D, Pizzuto F, Venkatraman ES, Brown C, Curtin JP.

Eur J Gynaecol Oncol. 1997;18(3):161-3.

PMID:
9174826
49.

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.

Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, Tong W, Norton L, Spriggs D.

J Clin Oncol. 1997 Jan;15(1):187-92.

PMID:
8996141

Supplemental Content

Loading ...
Support Center